{"protocolSection": {"identificationModule": {"nctId": "NCT02091440", "orgStudyIdInfo": {"id": "HW005/ Japan"}, "organization": {"fullName": "Medtronic Cardiac Rhythm and Heart Failure", "class": "INDUSTRY"}, "briefTitle": "Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan", "officialTitle": "Clinical Evaluation of the HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure", "acronym": "HW005"}, "statusModule": {"statusVerifiedDate": "2019-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-03"}, "primaryCompletionDateStruct": {"date": "2015-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-12-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-03-17", "studyFirstSubmitQcDate": "2014-03-17", "studyFirstPostDateStruct": {"date": "2014-03-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-05-07", "resultsFirstSubmitQcDate": "2019-07-26", "resultsFirstPostDateStruct": {"date": "2019-09-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-07-26", "lastUpdatePostDateStruct": {"date": "2019-09-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Medtronic Cardiac Rhythm and Heart Failure", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to evaluate the safety and effectiveness of the HW005 System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death.", "detailedDescription": "The primary endpoint is success at 180 days which is expressed as a simple proportion and defined as alive on the originally implanted HW005 or transplanted or explanted for recovery. Patients must survive 60 days post-explant for recovery to be considered successful. The primary endpoint is not statistically powered. The six eligible implanted cases will be evaluated as a proportion of success accompanied by a 95% exact confidence interval and presented alongside the ADVANCE results for visual comparison."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Medical Device", "Thoracic Surgical Procedure", "Pumps Heart Assist", "Ventricular Assist Device"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 6, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "HW005 Ventricular Assist System", "type": "OTHER", "description": "Implant of the HW005 Ventricular Assist System.", "interventionNames": ["Device: Implant of the HW005 Ventricular Assist System."]}], "interventions": [{"type": "DEVICE", "name": "Implant of the HW005 Ventricular Assist System.", "description": "The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.", "armGroupLabels": ["HW005 Ventricular Assist System"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days", "description": "The primary endpoint is success at 180 days which is defined as alive on the originally implanted HW005 Ventricular Assist System or transplanted or explanted for recovery. Patients must survive 60 days post-explant for recovery to be considered successful.", "timeFrame": "180 days"}], "secondaryOutcomes": [{"measure": "Number of Participants Alive on the Implanted HW005 Ventricular Assist System at 180 Days", "timeFrame": "180 days"}, {"measure": "Incidence of All Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)", "description": "SAEs are defined as events that result in death, are life-threatening, result in permanent disability, require medical treatment to prevent permanent disability or require surgical intervention or hospitalization.\n\nUADEs are defined as any serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report.\n\nEvents were categorized using the Japanese registry for Mechanically Assisted Circulatory Support (J-MACS) definitions.", "timeFrame": "Through study completion, an average of 44.5 months"}, {"measure": "Incidence of All Device Failures and Device Malfunctions.", "description": "The device failures and malfunctions are the failures on pumping function due to thrombosis inside/outside of the implanted pump, the mechanical failures of the implanted components, the mechanical failures of the external components and the failures due to the user.\n\nEvents were categorized using the J-MACS definitions.", "timeFrame": "Through study completion, an average of 44.5 months"}, {"measure": "Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life Score at 6 and 24 Months", "description": "The KCCQ is a self-evaluation questionnaire for patients with heart failure to assess the severity of their symptoms how it may affect their lives. Scores range between 0 (worst) - 100 (best).\n\nValues in the table were calculated as the value at Month 6 (180 days) minus Screening and at Month 24 (after FU completion) minus Screening.\n\nThe positive change in KCCQ score indicates an improvement in patient Quality of Life.", "timeFrame": "Screening, Month 6 (180 days) and Month 24 (after follow-up (FU) completion)"}, {"measure": "Change in NYHA Patient Classification (Patient Functional Status) at 6 and 24 Months", "description": "The New York Heart Association (NYHA) Functional Classification places patients with heart failure in one of four categories based on how much they are limited during physical activity.\n\nClass I (best): No limitation of physical activity.\n\nClass II: Slight limitation of physical activity. Comfortable at rest.\n\nClass III: Marked limitation of physical activity. Comfortable at rest.\n\nClass IV (worst): Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.\n\nA shift from a higher class (e.g. Class IV) to a lower class (e.g. Class II) indicates an improvement in patient health and functional status.", "timeFrame": "Screening, Month 6 (180 days) and Month 24 (after FU completion)"}, {"measure": "Change in Patient 6-minute Walk Distance (Patient Functional Status) at 6 and 24 Months", "description": "For the 6-minute walk test, the patient is asked to walk for 6 minutes. The total distance walked is measured.\n\nValues in the table were calculated as the value at Month 6 (180 days) minus Screening and at Month 24 (after FU completion) minus Screening.\n\nA positive change in 6-minute walk distance indicates an improvement in health and functional status.", "timeFrame": "Screening, Month 6 (180 days) and Month 24 (after FU completion)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with irreversible end-stage heart failure of New York Heart Association (NYHA) class III or IV and a history of class IV who are eligible for heart transplantation.\n2. Patients who are dependent on medication of inotropes or intra-aortic balloon pump (IABP).\n3. Body Surface Area (BSA) \u22651.2 m2. In addition other factors may be taken into consideration, including chest size, abdominal fat (lack of abdominal fat may preclude a pump pocket) and any other physical characteristics that might be benefited by an intra-pericardial pump in a small person.\n4. Patients who are aged less than 65 years of age.\n5. Patients must be able to understand the limits and complications associated with the HW005 Ventricular Assist System.\n6. Female patients of childbearing potential must agree on contraception for the duration of the study.\n7. The patient or the legal representative has signed the informed consent form.\n\nExclusion Criteria:\n\n1. Severe illness other than heart disease which would exclude cardiac transplantation.\n2. Inadequate family/social support.\n3. Active, uncontrolled infection despite appropriate antibiotic, antiviral or antifungal treatment.\n4. Existence of any ongoing mechanical circulatory support (MCS) other than an IABP.\n5. Prior cardiac transplant or cardiomyoplasty.\n6. Acute myocardial infarction within 14 days of implant.\n7. Uncorrected thrombocytopenia or generalized coagulopathy.\n8. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.\n9. Patients for whom the use of a left ventricular assist device (LVAD) is contraindicated due to an ongoing aortic/cardiac aneurysm, intraventricular septum rupture and/or use of a mechanical heart valve.\n10. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy.\n11. Patients with irreversible hepatic dysfunction.\n12. Patients with irreversible renal dysfunction.\n13. Pregnancy.\n14. Patients with serious chronic obstructive pulmonary disease (COPD) (Forced Expiratory Volume in the first second (FEV1) \\< 50%).\n15. Pulmonary vascular resistance is unresponsive (fixed) to pharmacologic manipulation as demonstrated by a pulmonary artery systolic pressure exceeding 60mmHg in conjunction with any one of the two following variables:\n\n    * Pulmonary vascular resistance is greater than 6 Woods Units or\n    * Transpulmonary gradient exceeds 15 mmHg\n16. Cardiothoracic surgery within 14 days of implantation.\n17. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities.\n18. Pulmonary embolus within three weeks of enrollment as documented by computed tomography (CT) scan or nuclear scan.\n19. Patients have moderate to severe aortic insufficiency without plans for correction during pump implantation surgery. Correction may include aortic valve repair at the time of implant.\n20. The patient who has advanced calcification in the ascending aorta and/or the descending aorta.\n21. Serious right heart failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) at the time of screening.\n22. Patients with severe central nervous system disorder or severe cerebral vascular disorder.\n23. Patients with a history of drug intoxication, alcohol dependence.\n24. Patients unwilling or unable to comply with study requirements.\n25. Patients who refuse transfusion.\n26. Patients who in the investigator judgement are deemed to be unsuitable as a subject.\n27. Patients who are participating in another clinical trial involving investigational drugs or devices.", "healthyVolunteers": false, "sex": "ALL", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Yoshiki Sawa, MD", "affiliation": "Osaka University Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Kyushu University Hospital", "city": "Fukuoka", "state": "Kyushu", "zip": "812-8582", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Tohoku University Hospital", "city": "Sendai", "state": "Tohoku", "zip": "980-8547", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "Osaka University Hospital", "city": "Osaka", "zip": "565-0871", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "National Cerebral and Cardiovascular Center Hospital", "city": "Osaka", "zip": "565-8565", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "The University of Tokyo Hospital", "city": "Tokyo", "zip": "113-8655", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Primary Endpoint (Success at 180 Days)", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Overall Survival at 180 Days", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}, {"title": "New York Heart Association (NYHA) Classification", "description": "The New York Heart Association (NYHA) Functional Classification places patients with heart failure in one of four categories based on how much they are limited during physical activity.\n\nClass I (best): No limitation of physical activity.\n\nClass II: Slight limitation of physical activity. Comfortable at rest.\n\nClass III: Marked limitation of physical activity. Comfortable at rest.\n\nClass IV (worst): Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Class I", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Class II", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Class III", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "Class IV", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}, {"title": "Six-Minute Walk Test", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "meters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "135.8", "spread": "160.12"}]}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire (KCCQ) scores", "description": "The KCCQ is a self-evaluation questionnaire for patients with heart failure to assess the severity of their symptoms how it may affect their lives. All scores range between 0 (worst) - 100 (best).\n\nFor example: Social Limitation score of 100 means no social limitation at all\n\nTotal Symptom Score: mean of Symptom Frequency and Symptom Burden scores\n\nOverall Summary Score: mean of Physical Limitation, Symptom Stability, Total Symptom, Quality of Life and Social Limitation scores\n\nClinical Summary Score: mean of Physical Limitation and Total Symptom scores", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"title": "KCCQ Physical Limitation", "categories": [{"measurements": [{"groupId": "BG000", "value": "45.0", "spread": "31.69"}]}]}, {"title": "KCCQ Symptom Stability", "categories": [{"measurements": [{"groupId": "BG000", "value": "37.5", "spread": "26.22"}]}]}, {"title": "KCCQ Self-Efficacy", "categories": [{"measurements": [{"groupId": "BG000", "value": "75.0", "spread": "22.36"}]}]}, {"title": "KCCQ Quality of Life", "categories": [{"measurements": [{"groupId": "BG000", "value": "31.9", "spread": "27.09"}]}]}, {"title": "KCCQ Social Limitation", "categories": [{"measurements": [{"groupId": "BG000", "value": "9.4", "spread": "13.26"}]}]}, {"title": "KCCQ Overall Summary Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "45.5", "spread": "28.44"}]}]}, {"title": "KCCQ Clinical Summary Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "56.4", "spread": "33.89"}]}]}, {"title": "KCCQ Symptom Frequency", "categories": [{"measurements": [{"groupId": "BG000", "value": "66.0", "spread": "39.91"}]}]}, {"title": "KCCQ Symptom Burden", "categories": [{"measurements": [{"groupId": "BG000", "value": "69.4", "spread": "38.97"}]}]}, {"title": "KCCQ Total Symptom Score", "categories": [{"measurements": [{"groupId": "BG000", "value": "67.7", "spread": "39.32"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants Alive on the Implanted HW005 Ventricular Assist System or Transplanted or Explanted for Recovery at 180 Days", "description": "The primary endpoint is success at 180 days which is defined as alive on the originally implanted HW005 Ventricular Assist System or transplanted or explanted for recovery. Patients must survive 60 days post-explant for recovery to be considered successful.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "180 days", "groups": [{"id": "OG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Single group", "paramType": "Proportion", "paramValue": "100", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Number of Participants Alive on the Implanted HW005 Ventricular Assist System at 180 Days", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "180 days", "groups": [{"id": "OG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Single group", "paramType": "Kaplan-Meier Survival", "paramValue": "100", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Incidence of All Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)", "description": "SAEs are defined as events that result in death, are life-threatening, result in permanent disability, require medical treatment to prevent permanent disability or require surgical intervention or hospitalization.\n\nUADEs are defined as any serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis report.\n\nEvents were categorized using the Japanese registry for Mechanically Assisted Circulatory Support (J-MACS) definitions.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "event rate per patient year", "timeFrame": "Through study completion, an average of 44.5 months", "groups": [{"id": "OG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"title": "J-MACS SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.24"}]}]}, {"title": "UADEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Single group", "paramType": "Incidence", "paramValue": "1.24", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Incidence of All Device Failures and Device Malfunctions.", "description": "The device failures and malfunctions are the failures on pumping function due to thrombosis inside/outside of the implanted pump, the mechanical failures of the implanted components, the mechanical failures of the external components and the failures due to the user.\n\nEvents were categorized using the J-MACS definitions.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "event rate per patient year", "timeFrame": "Through study completion, an average of 44.5 months", "groups": [{"id": "OG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.66"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Single group", "paramType": "Incidence", "paramValue": "1.66", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Quality of Life Score at 6 and 24 Months", "description": "The KCCQ is a self-evaluation questionnaire for patients with heart failure to assess the severity of their symptoms how it may affect their lives. Scores range between 0 (worst) - 100 (best).\n\nValues in the table were calculated as the value at Month 6 (180 days) minus Screening and at Month 24 (after FU completion) minus Screening.\n\nThe positive change in KCCQ score indicates an improvement in patient Quality of Life.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Screening, Month 6 (180 days) and Month 24 (after follow-up (FU) completion)", "groups": [{"id": "OG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"title": "Month 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.2", "spread": "12.55"}]}]}, {"title": "Month 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.4", "spread": "11.39"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Single group", "paramType": "Change from baseline", "paramValue": "19.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.5", "ciUpperLimit": "31.4", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "11.39", "estimateComment": "Confidence interval based on t-distribution."}]}, {"type": "SECONDARY", "title": "Change in NYHA Patient Classification (Patient Functional Status) at 6 and 24 Months", "description": "The New York Heart Association (NYHA) Functional Classification places patients with heart failure in one of four categories based on how much they are limited during physical activity.\n\nClass I (best): No limitation of physical activity.\n\nClass II: Slight limitation of physical activity. Comfortable at rest.\n\nClass III: Marked limitation of physical activity. Comfortable at rest.\n\nClass IV (worst): Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.\n\nA shift from a higher class (e.g. Class IV) to a lower class (e.g. Class II) indicates an improvement in patient health and functional status.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Screening, Month 6 (180 days) and Month 24 (after FU completion)", "groups": [{"id": "OG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"title": "Screening", "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "0"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "0"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "3"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Month 6", "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "1"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "5"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "0"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Month 24", "categories": [{"title": "Class I", "measurements": [{"groupId": "OG000", "value": "2"}]}, {"title": "Class II", "measurements": [{"groupId": "OG000", "value": "3"}]}, {"title": "Class III", "measurements": [{"groupId": "OG000", "value": "1"}]}, {"title": "Class IV", "measurements": [{"groupId": "OG000", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Single group", "paramType": "Percentage change", "paramValue": "-83.33", "ciNumSides": "TWO_SIDED", "estimateComment": "Percentage change from 24 months to screening in NYHA classes III and IV. Percentage change is 16.67% - 100% = -83.33%"}]}, {"type": "SECONDARY", "title": "Change in Patient 6-minute Walk Distance (Patient Functional Status) at 6 and 24 Months", "description": "For the 6-minute walk test, the patient is asked to walk for 6 minutes. The total distance walked is measured.\n\nValues in the table were calculated as the value at Month 6 (180 days) minus Screening and at Month 24 (after FU completion) minus Screening.\n\nA positive change in 6-minute walk distance indicates an improvement in health and functional status.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Meters", "timeFrame": "Screening, Month 6 (180 days) and Month 24 (after FU completion)", "groups": [{"id": "OG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}]}], "classes": [{"title": "Month 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "198.2", "spread": "217.01"}]}]}, {"title": "Month 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "130.0", "spread": "275.32"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "nonInferiorityComment": "Single group", "paramType": "Change from baseline", "paramValue": "130.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-158.9", "ciUpperLimit": "418.9", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "275.32", "estimateComment": "Confidence interval based on t-distribution."}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Through study completion, an average of 44.5 months", "eventGroups": [{"id": "EG000", "title": "HW005 Ventricular Assist System", "description": "Implant of the HW005 Ventricular Assist System.: The HW005 Pump is an implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.", "deathsNumAffected": 2, "deathsNumAtRisk": 6, "seriousNumAffected": 5, "seriousNumAtRisk": 6, "otherNumAffected": 6, "otherNumAtRisk": 6}], "seriousEvents": [{"term": "Bleeding requiring re-hospitalization", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Bleeding requiring re-operation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Ventricular Cardiac Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Supraventricular Cardiac Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Driveline Exit Site Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Hemorrhagic Cerebrovascular Accident", "organSystem": "Vascular disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Pericardial Fluid Collection", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Chronic Renal Dysfunction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Respiratory Dysfunction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Right Heart Failure requiring inotropic therapy", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Other", "organSystem": "General disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 6}]}], "otherEvents": [{"term": "Bleeding requiring re-hospitalization", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Bleeding requiring re-operation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Ventricular Cardiac Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 6}]}, {"term": "Supraventricular Cardiac Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 6}]}, {"term": "Device Malfunction/Failure", "organSystem": "Product Issues", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Driveline Exit Site Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Hemorrhagic Cerebrovascular Accident", "organSystem": "Vascular disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Pericardial Fluid Collection", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 6}]}, {"term": "Acute Renal Dysfunction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Chronic Renal Dysfunction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Respiratory Dysfunction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Right Heart Failure requiring inotropic therapy", "organSystem": "Cardiac disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Other", "organSystem": "General disorders", "sourceVocabulary": "J-MACS", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 86, "numAffected": 6, "numAtRisk": 6}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The PI cannot disclose the trial results without the sponsor's permission. The disclosure restriction is not limited by a set period."}, "pointOfContact": {"title": "Prof. Yoshiki Sawa", "organization": "Osaka University Hospital", "email": "sawa@surg1.med.osaka-u.ac.jp", "phone": "+81 668793160"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}